8 recruiting, 2 not yet recruiting, 2 unknown, 1 terminated. 11 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 7, Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Advanced Esophageal Squamous Cell Carcinoma: new trials by email Literature Review of Advanced Esophageal Squamous Cell Carcinoma trials Research Report on Advanced Esophageal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-14 |
| A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma SHR-9839(sc) for Injection, SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 84 | 2026-09-07 | 2026-09-16 |
| A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma JS212, JS001, 5-FU - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 280 | 2026-04-13 | 2026-04-22 |
| A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma anlotinib combined with benmelstobart, Toripalimab Combined with Chemotherapy - Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 578 | 2026-04-01 | 2026-03-03 |
| A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy YL201, Paclitaxel, Docetaxel - Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 440 | 2026-03-24 | 2026-07-16 |
| Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma. Concurrent chemoradiotherapy (cCRT), Induced treatment - Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 50 | 2026-03-10 | 2026-03-13 |
| AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients Ivonescimab combined with albumin paclitaxel and cisplatin - ESCC, Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-11-16 | 2025-01-22 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma simmitinib plus irinotecan liposome, irinotecan liposome, irinotecan - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Runshi Pharmaceutical Technology Co., Ltd | 138 | 2024-03-15 | 2024-07-22 |
| A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers HMBD-001, Docetaxel, Cetuximab - Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Hummingbird Bioscience | 398 | 2024-02-05 | 2026-05-27 |
| Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, Penpulimab injection, Paclitaxel, Cisplatin, TQB2618 injection, Penpulimab injection, TQB3617capsules - Advanced Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 34 | 2023-05-26 | 2025-07-16 |
| To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC Afatinib, Irinotecan - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Peking University | 72 | 2023-02-09 | 2023-04-19 |
| Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma Anlotinib/Penpulimab/Chemotherapy, Penpulimab/Chemotherapy - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 100 | 2022-09-02 | 2024-12-30 |
Carcinoma, Non-Small-Cell Lung (2) · Esophageal Squamous Cell Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1)
Carcinoma (3) · Head and Neck Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Squamous Cell (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Squamous Cell (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2)
Cisplatin (3) · Irinotecan (3) · Paclitaxel (3) · Docetaxel (2) · Drug Therapy (2) · Fluorouracil (2) · penpulimab (2) · Afatinib (1) · Cetuximab (1) · Chemoradiotherapy (1) · Home Care Services (1) · House Calls (1) · Leucovorin (1) · Nivolumab (1) · Oxaliplatin (1)
BeOne Medicines (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Fudan University (1) · Hummingbird Bioscience (1) · Mayo Clinic (1) · MediLink Therapeutics (Suzhou) Co., Ltd. (1) · Nanfang Hospital, Southern Medical University (1) · Peking University (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Shanghai Runshi Pharmaceutical Technology Co., Ltd (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · The First Affiliated Hospital of Zhengzhou University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (9) · Australia (1) · Japan (1) · Moldova (1) · Singapore (1) · South Korea (1) · Taiwan (1) · United States (1)
Roxana S. Dronca, M.D. (1) · Yanqiao Zhang, Ph.D (1)